Ghosts of Eternity

The heavy glass doors slid shut and locked, instantly severing the clamor of the banquet hall. Seohan and Seoyun walked down the dark navy-carpeted corridor and stepped into the private elevator. A brief silence settled between them as the floor numbers climbed rapidly toward the topmost level.

Ding.

As the doors parted, the rooftop terrace opened before them, revealing the traditional tiled roofs of the State Guest House and the sprawling lights of Seoul below. A night breeze slipped through the open space, stirring the stagnant indoor air. The wind gently caught the hem of Seoyun’s silk shirt.

“What do you think aging is?”

Seohan broke the silence first.

Seoyun turned her head to look at him. As someone accustomed to navigating both the language of academia and institutional bureaucracy, her response was composed.

“Academically speaking, it is functional regression—biological wear and tear brought on by the immutable force of time. It is a natural phenomenon humanity has yet to overcome.”

“I have no intention of claiming that we are curing aging.”

Seohan switched on his tablet. Blue waveforms and brief strings of data flickered to life in the darkness.

“That word is too big. When a word is too large, desire attaches itself to it before the data even has a chance.”

Seoyun’s eyes scanned the screen, reading between the lines of the metrics and graphs. She did not ask a question right away.

While looking at the waveforms on the tablet, she simultaneously pictured the faces of three men left behind in the banquet hall: Hyunjin Jeong, Uihyeon Jeong, and Taemin Gu. They were all faces that had already begun to conceal their aging—faces where fatigue had lessened, skin had tightened, and desire had been resurrected.

They would not perceive Ghost as a mere therapeutic drug. They would read it as a right to reclaim what was lost.

In that moment, Seoyun realized that the danger of this substance lay not just in its toxicity or efficacy. If Ghost actually worked, it would no longer be a drug treating a single disease; it would disrupt the social contract known as 'natural decline.'

The moment that consensus shattered, the first to move would not be the patients. It would be the wealthy. The powerful. Those who detested growing old more than anything else. Seoyun knew that sequence all too well.

“Why this specific axis?” Seoyun asked.

“Aether Bio can be fully justified as a company based on oncology alone. Yet you are targeting sleep, recovery, focus, and desire. These resemble human states rather than actual diseases.”

“When a state breaks down, it becomes a disease.”

“And who draws that line?”

“The data draws it.”

Seoyun did not accept his answer immediately.

“People say it is only natural to sleep less, recover slower, lose focus, and desire less as they age. They call it natural.”

“Calling something 'natural' usually just means we haven't intervened yet.”

Seohan swiped the tablet screen. Blue waveforms crested and fell at regular intervals. It was not a flat, sustained graph; rather, it was a structure defined by sharp, recurring spikes.

“Previous studies only looked at the substance itself,” Seohan said.

“Ghost was abandoned long ago after failing to demonstrate efficacy in Phase 2 clinical trials. However, I believe the failure lay not in the substance, but in its rhythm.”

“Pulsatility,” Seoyun said, watching the screen.

“Yes. The human body does not maintain hormones at a flat level. They spike when needed and drop immediately. Receptors read that waveform as a signal.”

Seohan pointed to one of the peaks on the graph with his finger.

“The previous research team kept flooding the bloodstream. When you do that, the receptors can no longer read the signal as a signal. They process it as noise. Eventually, they desensitize, and the response vanishes.”

Seoyun kept her eyes fixed on the screen.

“So, even with the exact same substance, changing the interval alters the meaning entirely.”

“The substance is a word. The interval is a sentence.”

A faint shift rippled through Seoyun’s gaze. It was an unexpected metaphor—sounding less like a scientist and more like her own language of institutional rhetoric.

“Ghost is not a drug that injects vitality. It is a signal that coaxes the body into rereading its lost rhythm.”

Seoyun fell silent for a moment. Gripping the cold terrace railing, she stared at the screen in Seohan’s hand, the ambient indoor light fracturing minutely in her eyes.

What she was looking at was neither a simple molecular structure nor mere data. It was a sentence. What name would this substance carry within the system? Into what diagnostic boundaries would it be pushed? And at what point would it stop being read as an ordinary therapeutic and start being perceived as a substance that alters social contracts and macroeconomic indicators?

“This is dangerous,” Seoyun said quietly.

Seohan turned his head.

“Are you referring to toxicity?”

“No. The sentence.”

Seoyun’s voice was low and firm. She glanced back toward the banquet hall. Beyond the thick glass doors, faint sounds of laughter and clinking glasses still drifted out. The people in that room would all believe they were being rational. National strategy, industrial growth, future engines of the economy, global competitiveness—there were plenty of plausible catchphrases.

Stolen from NovelFire, this story should be reported if encountered on Amazon.

Yet, if Ghost were placed right in front of them, the first phrase to slip out would be entirely different: 'Me first.' Seoyun knew this truth too well.

“The moment the word 'aging' is attached, this stops being a medicine and becomes a matter of rationing,” her voice remained low and steady.

“Who gets it first? Who pays for it? Do we put it under national health insurance, or leave it as an expensive private treatment? The moment rumors circulate that the military, high-ranking bureaucrats, and conglomerate executives have gained priority access, public outrage will explode.”

Seohan watched her without a word.

“If the efficacy is weak, you will be decried as a fraud; if the efficacy is strong, it becomes even more dangerous. Strong efficacy invariably triggers a battle over access. And access is not a matter of medicine—it is a matter of politics.”

“Are you saying strong efficacy is the problem?”

“No. The problem is the first sentence used to explain that strong efficacy.”

Seoyun lightly tapped the tablet screen.

“The moment you write 'anti-aging drug,' people immediately visualize their own parents, their own lifespan, their own wealth, and their own social class. In that instant, the data vanishes, and only fury remains.”

“Are you suggesting we evade the fury?”

“No. I am suggesting we delay the sequence of its arrival.”

Seoyun looked Seohan straight in the eye.

“A product trying to survive within the regulatory system must never appear powerful from the start. Initially, it must be narrow, tedious, and difficult to refute.”

Seoyun took the tablet from Seohan’s hand and opened a blank memo application. She began by drawing a line clean through four specific words:

[Aging] [Rejuvenation] [Youth] [Life Extension]

“Do not use these words.”

Seohan looked down at the screen.

“Those are exactly the words investors would love.”

“Which is precisely why you cannot use them.”

Beneath the crossed-out text, Seoyun neatly wrote down a new set of terms:

[Age-Related Functional Decline]

[Neuroendocrine Rhythm Regulation]

[Sleep Quality and Recovery Time Indicators]

[Quality of Life Outcome Variables]

“Official documentation must take this route. Given the exact same data, the words above incite madness, while the words below invite evaluation. People feel entirely different levels of outrage depending on the name attached to the same data. We must narrow the phrasing strictly to indications and endpoints proven solely by numbers.”

Seoyun immediately jotted down a brief sentence below the list:

Evaluation of the potential to improve sleep quality, recovery time, and quality of life indicators through neuroendocrine rhythm regulation in patient populations with age-related functional decline.

Seohan stared down at the sentence.

“It’s long.”

“Which is why it is safe.”

“……”

Seoyun was not joking in the slightest.

“A sentence that is too easy to read will be seized by politicians; a sentence that is too alluring will be hijacked by investors. And a sentence that is too terrifying will be torn apart by the media. Official documentation must be so tedious that none of the three can grasp it cleanly at once.”

Seohan nodded ever so slightly.

Seoyun looked back down at the memo.

“The name Ghost isn’t the issue. The name has already been given, and people will ultimately remember it. What matters is the explanation attached right next to that name.”

She typed a new line:

[Ghost: A candidate molecule for age-related functional decline and neuroendocrine rhythm abnormalities.]

Then, she immediately shook her head.

“Even this is still too big.”

Seohan did not reply.

Seoyun deleted the phrase 'age-related' and typed again:

[A candidate molecule for specific rare indications accompanied by neuroendocrine rhythm abnormalities.]

“The initial documentation must begin at this scale.”

“It seems too small.”

“It must be small to pass.”

“It diminishes the significance.”

“The significance can be expanded by the data later. If the sentence grows too large first, the data will never catch up.”

Seoyun handed the tablet back to Seohan.

“How are you envisioning the clinical trial design?”

“A straightforward approach. Upon completing Phase 1, we will proceed to Phase 2 efficacy evaluation using the rare indication originally pursued by the previous developer. Nothing extraordinary up to this point.”

“And after that?”

“Once the data is secured, we broaden the evaluation endpoints,” Seohan stated briefly.

“After verifying safety and efficacy through the rare indication, we can separately append functional decline and quality of life endpoints. Sleep quality, recovery time, sustained attention span, fatigue tolerance—all of these are parameters that can be translated into numbers.”

“And the target subjects?” Seoyun asked.

“Initially, it will be the patient population meeting the criteria for the rare indication.”

“And after that?”

Seohan paused for a moment.

“We can expand it to cohorts displaying clear indicators of functional decline.”

“That sentence is the most dangerous of all,” Seoyun countered immediately.

“Indicators of functional decline exist in everyone. Too many people feel that their sleep quality is poor, their recovery is sluggish, their focus is slipping, and their desires are waning. That sentence will quickly mutate into a universal claim: 'I am a candidate too.'”

“If their actual objective metrics match, they could legally become candidates.”

“Medically, perhaps. But socially, absolutely not.”

Seoyun looked down at Seoul beyond the railing.

“If Ghost demonstrates undeniable efficacy, people who are not sick will clamor to become patients. From that point onward, the line must be drawn by the regulatory system, not by doctors.”

“The criterion for drawing that line is data.”

“And the system is the very entity that interprets that data.”

Seohan stepped back, summarizing the path forward.

“The Phase 1 safety trials will be conducted under my management. There is no immediate need for you to move, Chief Baek. However, please look ahead and identify what regulatory pathways will be required by the time we enter Phase 2.”

“Meaning this could escalate into an issue that transcends routine approval procedures.”

“If the data comes out that way, yes.”

“Then we must narrow the sentence even further,” Seoyun said calmly.

“You must not bring up terms like 'national strategic asset' from the outset. We must first find a viable path within the existing framework—rare indications, functional metrics, quality of life improvements. Then, if the data is powerful enough, phrases like 'regulatory sandbox' or 'national project' can naturally be attached.”

“Where will the resistance come from?” Seohan asked.

“Everywhere.” Seoyun did not hesitate.

“The Ministry of Food and Drug Safety will question the indication. Academic societies will challenge the exaggeration of the mechanism. The national health insurance review boards will foresee a financial nightmare, and the media will run headlines calling it an 'elixir for the rich.' Even bioethics committees will mobilize on the sheer phrasing of intervening in the natural human lifespan.”

“We can answer all of it with data.”

“No. Data can be an answer, but it is never the first sentence.”

Seoyun turned off the tablet screen.

“If the first sentence is wrong, the data will only sound like an excuse.”

Seohan stared at the darkened screen for a moment before speaking dryly.

“What I need from you is not a guide to approval protocols. The legal team can handle that much.”

Seoyun’s eyes narrowed.

“Then what is it you want from me?”

“A sentence that survives.”

Seohan spoke with a face entirely devoid of exaggeration.

“I know what the data means. But I do not know what name that meaning must take within the system to endure over time. That is your domain, Chief Baek.”

Seoyun looked at the blank, dark screen of the tablet instead of giving an answer.

Ghost. A substance that had yet to secure a proper place anywhere in official documentation. Yet the moment data was attached to it, an indication would be anchored, and the appropriate institutional sentences would be layered over it—that ghost would begin to walk the corridors of the establishment.

Only then did Seoyun realize it.

Lee Seohan was not a man seeking to rule the world. He was simply someone who brought forth things the world had not yet named—bringing them far too early, and far too calmly. And such a person, at times, was infinitely more dangerous than any ruler.

“We will build the sentences first,”

Seoyun said softly.

“And then, we will forge a path for that name to survive within the system.”